Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingsong Fan

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Scientific Reports|March 30, 2020
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with SchizophreniaDalton King, Christiana Iwuagwu, Jim Cook, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Toxicology and Applied Pharmacology|April 6, 2020
Corrigendum to "A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm" [Toxicology and Applied Pharmacology volume 394C (2020) 114961]Bradley J Ridder, Derek J Leishman, Matthew Bridgland-Taylor, et al.
Toxicology and Applied Pharmacology|March 27, 2020
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigmBradley J Ridder, Derek J Leishman, Matthew Bridgland-Taylor, et al.
Journal of Medicinal Chemistry|May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological DisordersQingjie Liu, Qing Shi, David Marcoux, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Scientific Reports|March 30, 2020
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with SchizophreniaDalton King, Christiana Iwuagwu, Jim Cook, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Toxicology and Applied Pharmacology|April 6, 2020
Corrigendum to "A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm" [Toxicology and Applied Pharmacology volume 394C (2020) 114961]Bradley J Ridder, Derek J Leishman, Matthew Bridgland-Taylor, et al.
Toxicology and Applied Pharmacology|March 27, 2020
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigmBradley J Ridder, Derek J Leishman, Matthew Bridgland-Taylor, et al.
Journal of Medicinal Chemistry|May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological DisordersQingjie Liu, Qing Shi, David Marcoux, et al.
Pageof 2